Search

Displaying results 2011 - 2020 of 8573 in total
  1. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    [A262960] Berdazimer was previously investigated as a potential treatment for molluscum contagiosum, a viral cutaneous infection mainly affecting children, sexually active adults, and immunocompromised … [A262965] Previously, the first line treatment for molluscum contagiosum was surgical excision, although it poses challenges such as repeated doctor visits, post-surgical scarring and skin discoloration

  2. Drug

    Dasabuvir

    go.drugbank.com/drugs/DB09183
    Approved

    Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Dasabuvir. … Dasabuvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  3. Drug

    Anisotropine methylbromide

    go.drugbank.com/drugs/DB00517
    Approved

    Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.

  4. Drug

    Tolfenamic acid

    go.drugbank.com/drugs/DB09216
    Approved

    [A31824] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam. … By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291]

  5. Drug

    Binimetinib

    go.drugbank.com/drugs/DB11967
    ApprovedInvestigational

    Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib]. … combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as

  6. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    such as cancer and rheumatoid arthritis. … This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases

  7. Drug

    2-Methoxyestradiol

    go.drugbank.com/drugs/DB02342
    Investigational

    It has undergone Phase 1 clinical trials against breast cancers and preclinical studies suggest that 2ME2 could also be effective against inflammatory diseases such as rheumatoid arthritis.

  8. Drug

    Dordaviprone

    go.drugbank.com/drugs/DB14844
    ApprovedInvestigational

    [L53833] Dordaviprone was initially studied as an anticancer agent that induces TNF-Related Apoptosis-Inducing Ligand (TRAIL). … On August 6, 2025, dordaviprone was granted accelerated approval by the FDA.[L53838] It is used to treat patients with diffuse midline glioma harboring an H3 K27M mutation.

  9. Drug

    Dithiazanine

    go.drugbank.com/drugs/DB11516
    ApprovedVet approvedWithdrawn

    Dithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032] … Dithiazanine iodide was associated with eight fatal cases of severe acidosis and shock between 1961 and 1964.

  10. Drug

    Pentolinium

    go.drugbank.com/drugs/DB01090
    Approved

    Pentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.